Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$16.92 USD
+0.43 (2.61%)
Updated May 20, 2024 04:00 PM ET
After-Market: $16.93 +0.01 (0.06%) 4:32 PM ET
3-Hold of 5 3
B Value A Growth F Momentum A VGM
Brokerage Reports
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 301 - 320 ( 418 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Submission Complete - Acceptance Decision Next Catalyst
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Firdapse Poised for LEMS PDUFA and CMS Data in 2016
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.